{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:56:55Z","timestamp":1773712615442,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.msard.2023.104564","type":"journal-article","created":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T17:22:57Z","timestamp":1676222577000},"page":"104564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis"],"prefix":"10.1016","volume":"71","author":[{"given":"Ali Ussama","family":"Fakih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Paybast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-0911","authenticated-orcid":false,"given":"Abdorreza","family":"Naser Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2023.104564_bib0015","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2023.104564_bib0004","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study","volume":"86","author":"Barbin","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104564_bib0012","first-page":"12","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2023.104564_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/jpm12010119","article-title":"Escalation vs. early intense therapy in multiple sclerosis","volume":"12","author":"Casanova","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2023.104564_bib0019","article-title":"Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: a monocentric study","volume":"52","author":"de la Motte","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104564_bib0022","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00415-021-10708-1","article-title":"Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration","volume":"269","author":"Ferraro","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104564_bib0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ane.12864","article-title":"Real-life clinical use of natalizumab and fingolimod in Austria","volume":"137","author":"Guger","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2023.104564_bib0003","series-title":"Paradigm Shifts: Early Initiation of High-Efficacy Disease-Modifying Treatment in Multiple Sclerosis","first-page":"1473","author":"Hartung","year":"2021"},{"issue":"7","key":"10.1016\/j.msard.2023.104564_bib0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104564_bib0021","first-page":"2018","article-title":"Extensive multiple sclerosis reactivation after switching from fingolimod to rituximab","author":"Holm\u00f8y","year":"2018","journal-title":"Case Rep. Neurol. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.104564_bib0011","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1352458519858604","article-title":"Rituximab treatment for multiple sclerosis","volume":"26","author":"Ineichen","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104564_bib0008","first-page":"1","article-title":"Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod\u2014Potentials and risks of subsequent highly active agents","author":"Korsen","year":"2022","journal-title":"J. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2023.104564_bib0017","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1177\/1352458520927631","article-title":"Switching from natalizumab to ocrelizumab in patients with multiple sclerosis","volume":"26","author":"Levin","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2023.104564_bib0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2023.104564_bib0014","article-title":"Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: an observational study","volume":"36","author":"Moghadasi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104564_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104564_bib0009","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/CON.0000000000000739","article-title":"Management of multiple sclerosis relapses","volume":"25","author":"Repovic","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"10.1016\/j.msard.2023.104564_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419846818","article-title":"Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases","volume":"12","author":"Schmidt","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.104564_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2023.104564_bib0018","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/13524585211005657","article-title":"Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy","volume":"28","author":"Signoriello","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2023.104564_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2023.104564_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:11Z","timestamp":1761901451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":22,"alternative-id":["S2211034823000688"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104564","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104564"}}